Cell count ratios appear to predict thromboembolism in lymphomaJune 25, 2019Lymphoma & Plasma Cell DisordersPatient & Survivor Care
Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomasJune 21, 2019ImmunotherapyLymphoma & Plasma Cell DisordersImmuno-oncologyLeukemia, Myelodysplasia, Transplantation
5F9 plus rituximab take a bite out of drug-resistant NHLJune 18, 2019Lymphoma & Plasma Cell DisordersFollicular Lymphoma
‘Encouraging’ responses seen with durvalumab plus R-CHOP in DLBCLJune 17, 2019Lymphoma & Plasma Cell Disorders
R2 appears active in high-risk FL and MZLJune 14, 2019Lymphoma & Plasma Cell DisordersFollicular LymphomaRare Diseases
Triplet offers longest PFS yet seen in relapsed/refractory myelomaJune 12, 2019Lymphoma & Plasma Cell Disorders
Four-drug combo bests triplet in newly diagnosed myelomaJune 12, 2019Lymphoma & Plasma Cell Disorders
Inhibitor produces high response rate in relapsed/refractory FLJune 11, 2019Follicular LymphomaLymphoma & Plasma Cell Disorders
Chemo-free Smart Start regimen looks promising in poor-prognosis DLBCLJune 7, 2019Lymphoma & Plasma Cell Disorders
Daratumumab regimen shows benefit in transplant-ineligible myelomaMay 29, 2019Lymphoma & Plasma Cell Disorders
FDA approves lenalidomide/rituximab for previously treated FL, MZLMay 29, 2019Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Trial follow-up spotlights survival gains in follicular lymphomaMay 16, 2019Follicular LymphomaLymphoma & Plasma Cell Disorders
